Zusammenfassung
Patienten mit chronisch entzündlichen Darmerkrankungen haben ein erhöhtes Risiko im
Verlaufe ihrer Erkrankung ein kolorektales Karzinom (CRC) zu entwickeln. Das Risiko
an einem Kolonkarzinom zu erkranken ist bei Patienten mit Colitis ulcerosa (CU) bis
zu dreifach höher als in der Normalbevölkerung. Unter der Voraussetzung, dass das
Kolon befallen ist, gelten ähnliche Risikofaktoren auch für den M. Crohn (MC) [1], die Datenlage ist jedoch deutlich spärlicher.
Das Risiko hängt im Wesentlichen von der Dauer und Ausdehnung der Erkrankung ab [2]
[3]
[4]
[5], die Mortalität bei Patienten mit chronisch entzündlichen Darmerkrankungen ist dabei
höher als bei Patienten mit sporadischem kolorektalen Karzinom [6]. Insbesondere jüngere Patienten mit Colitis ulcerosa oder Crohn-Kolitis über 10
Jahre andauernder Krankheitsgeschichte und ausgedehntem Befall haben ein hohes relatives
Risiko (Alter 20-39 Jahre, RR 22) ein Karzinom zu entwickeln. Als Risikofaktoren sind
weiterhin lange Krankheitsdauer, gleichzeitige geringe Krankheitsaktivität, frühe
Erkrankung, gleichzeitig bestehende primär sklerosierende Cholangitis, Stenosen und
der Nachweis einer „Backwash Ileitis” etabliert. Das Fehlen einer adäquaten Überwachung
von Risikopatienten scheint ebenso wie eine unzureichende antientzündliche Therapie,
ein Folsäuremangel und evtl. sogar ein Nichtraucherstatus das Risiko eines Kolitis-assoziierten
Karzinoms (Ulcerative Colitis Associated Colorectal Cancer UCACRC) zu erhöhen [2]
[3]
[4]
[7]
[8]
[9]
[10]
[11]
[12]. Es gilt allgemein als akzeptiert, dass Dysplasien die Vorstufen des Kolitis-assoziierten
Karzinoms bilden und als solche als Marker für ein Karzinomrisiko darstellen. Obwohl
eindeutige Studien zum eigentlichen Nutzen fehlen wird daher eine Überwachung von
Patienten mit länger andauernden chronisch entzündlichen Darmerkrankungen zur Früherkennung
von Dysplasien und Karzinomen empfohlen [13]
[14]. Während diese Strategien zur Prävention des kolorektalen Karzinoms heute durch
Studien recht gut belegt sind, ist die Datenlage bezüglich einer Überwachungsstrategie
zur Prävention des Colitis ulcerosa-assoziierten Karzinoms wesentlich schlechter.
So bestehen große Unsicherheiten, welche Patientengruppe überwacht werden muss und
wie eine solche Überwachung aussehen sollte [15]. Generell wird empfohlen, alle Patienten mit früher Manifestation, langjährigem
und ausgedehntem Befall etwa 8-10 Jahre nach Erstmanifestation in ein Überwachungsprogramm
einzuschließen. Dieses Programm sollte derzeit eine hohe Koloskopie in ein- bis zweijährlichen
Intervallen mit der Entnahme von Stufenbiopsien zur frühzeitigen Entdeckung von Epitheldysplasien
beinhalten. Besonderer Wert sollte dabei auf reichliche bioptische Probenentnahmen
z. B. alle 10 cm des Darms und die konsequente Anwendung pathologischer Dysplasie-Kriterien
z. B. nach dem IBD-DMSG-Standard gelegt werden [16]
[17]. Bei Nachweis von highgrade-Dysplasien und DALM ist eine Proktokolektomie zu empfehlen,
bei Nachweis von low-grade-Dysplasien ist zumindest die Überwachung zu intensivieren
und auch hier ggfs. eine Proktokolektomie zu erwägen.
Abstract
Patients with chronic inflammatory bowel disease have a higher risk of developing
colorectal carcinoma (CRC) during the course of their disease. The risk of colon carcinoma
is up to three times higher in patients with ulcerative colitis than in the normal
population. When the colon is affected, similar risk factors also hold for patients
with Crohn's disease (CD) [1] although markedly few data are available.
The risk depends principally on the duration and extent of the disease [2]
[3]
[4]
[5], with the mortality being higher for patients with chronic inflammatory bowel disease
than for patients with sporadic colorectal carcinomas [6]. In particular, younger patients with ulcerative colitis or Crohn's colitis with
a duration of disease of more than 10 years and extensive attack have a high relative
risk of developing a carcinoma (age 20-39 years, RR 22). A long duration of disease
with concomitant low disease activity, early onset, a simultaneously existing primary
sclerorising cholangitis, stenoses, and the detection of backwash ileitis are still
considered as risk factors. The lack of an adequate control of risk patients as well
as an unsatisfactory anti-inflammation therapy, a folic acid deficiency and possibly,
also non-smoking status, appear to increase the risk of colitis-associated carcinoma
(ulcerative colitis associated colorectal cancer, UCACRC) [2]
[3]
[4]
[7]
[8]
[9]
[10]
[11]
[12]. It is generally accepted that dysplasias represent the precursors of colitis-associated
carcinoma and as such constitute a marker for the carcinoma risk. Although unambiguous
studies are lacking, the close monitoring for the early detection of dysplasias and
carcinomas in patients with long-duration chronic inflammatory bowel diseases is recommended
[13]
[14]. Although these strategies for the prevention of colorectal carcinoma are now well-founded
by studies, the available data on monitoring strategies for the prevention of ulcerative
colitis-associated carcinomas are much less extensive. Thus, there are large differences
of opinion as to which patient groups should be monitored and what such as monitoring
scheme should look like [15]. It is generally recommended to include all patients with long-duration and extensive
attack in a monitoring program at about 8-10 years after the first manifestation.
This program should involve a high coloscopy with serial biopsies for the early detection
of epithelial dysplasias at one to two year intervals. Particular attention should
be paid to obtaining sufficient biopsy samples, e. g., at about every 10 cm along
the bowel, and the consequent application of pathological dysplasia criteria, e. g.,
according to those set out in the IBD-DMSG standard [16]
[17]. On detection of high-grade dysplasia and DALM, a proctocolectomy is recommended,
on detection of low-grade dysplasias at least the monitoring should be intensified
and a proctocolectomy considered.
Schlüsselwörter
Colitis ulcerosa - Kolorektale Karzinome - Prävention - Diagnose
Key words
Ulcerative colitis - colorectal carcinoma - prevention - diagnosis
Literatur
- 1
Sachar D B.
Cancer in Crohn's disease. Sispelling the myths.
Gut.
1994;
35
651-655
- 2
Rosenqvist H, Ohrling H, Lagercrantz R, Edling N.
Ulcerative colitis and carcinoma coli.
Lancet.
1950;
1
906-908
- 3
Edwards F C, Truelove S C.
Course and prognosis of ulcerative colitis. IV: Carcinoma of colon.
Gut.
1964;
5
1-22
- 4
Connell W R, Leonard-Jones J E, Williams C B.
Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative
colitis.
Gastroenterology.
1994;
107
934-944
- 5
Devroede G J, Taylor W F, Sauer W G, Jackman R J, Stickler G B.
Cancer risk and life expectancy of children with ulcerative colitis.
N Engl J Med.
1971;
285
17-21
- 6 Ekbom A. Cancer in inflammatory bowel disease. In: Caprilli E (ed). Inflammatory
bowel disease. Schattauer, Stuttgart 1997; 91-97
- 7
Ekbom A, Helmick C, Zack M, Adami H O.
Ulcerative colitis and colorectal cancer: A population-based study.
N Engl J Med.
1990;
323
1228-1233
- 8
Weedon D D, Shorter R G, Illstrup D M, Huizenga K A, Taylor W F.
Crohn's disease and cancer.
N Engl J Med.
1973;
289
1099-1103
- 9
Softley A, Clamp S E, Watkinson G, Bouchier I A, Myren J, deDombal F T.
The natural history of inflammatory bowel disease: Has there been a change in the
last 20 years?.
Scand J Gastroenterol Suppl.
1988;
144
20-23
- 10
Richards M E, Rickert R R, Nance F C.
Crohn's disease-associated carcinoma: A poorly recognized complication of inflammatory
bowel disease.
Ann Surg.
1989;
209
764-773
- 11
Ekbom A, Helmick C, Zack M, Adami H O.
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement.
Lancet.
1990;
336
357-359
- 12
Heuschen U A, Hinz U, Allemeyer E H, Stern J, Lucas M, Autschback F, Herfarth C, Heuschen G.
Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis.
Gastroenterology.
2001;
120
747-841
- 13
Kornbluth A, Sachar D B.
Ulcerative colitis practice guidelines in adults.
Am J Gastroenterol.
1997;
92
204-211
- 14 Peppercorn M A, Odze R D. Colorectal cancer surveillance in inflammatory bowel
disease. UptoDate version11.03. www.uptodate.com
- 15
Snapper S B, Syngal S, Friedman L S.
Ulcerative colitis and colon cancer: more controversy than clarity.
Dig Dis.
1998;
16
81-87
- 16
Riddell R H, Goldman H, Ransohoff D F.
Dysplasia in inflammatory bowel disease: standardized classification with provisional
clinical application.
Hum Pathol.
1983;
14
931-968
- 17
Connell W R, Lennard-Jones J E, Williams C B, Falbot I C, Price A B, Wilkinson K H.
Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative
colitis.
Gastroenterology.
1994;
107
934-944
- 18
Gyde S N, Prior P, Allan R N. et al .
Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from
three centers.
Gut.
1988;
29
206-217
- 19
Lennard-Jones J E.
Cancer risk in ulcerative colitis: Surveillance or surgery.
Br J Surg.
1985;
72 (Suppl)
84-86
- 20
Lofberg R, Brostrom O, Karlen P.
Colonoscopic surveillance in long-standing total ulcerative colitis - a 15-year follow-up
study.
Gastroenterology.
1990;
99
1021-1031
- 21
Collins R H, Feldman M, Fordtran J S.
Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical
review.
N Engl J Med.
1987;
316
1654-1658
- 22
Katzka I, Brody R S, Morris E, Katz S.
Assessment of colorectal cancer risk in patients with ulcerative colitis: Experience
from a private practice.
Gastroenterology.
1983;
85
22-29
- 23
Mir-Madjlessi S H, Farrer R G, Easley K A, Beck G J.
Colorectal and extracolonic malignancy in ulcerative colitis.
Cancer.
1986;
58
1569-1574
- 24
Lennard-Jones J E, Melville D M, Morson B C, Ritchie J K, Williams C B.
Precancer and cancer in extensive ulcerative colitis: Findings among 401 patients
over 22 years.
Gut.
1990;
31
800-806
- 25
Langholz E, Munkholm P, Davidsen M, Binder V.
Colorectal cancer risk and mortality in patients with ulcerative colitis.
Gastroenterology.
1992;
103
1444-1451
- 26
Greenstein A J, Sachar D B, Smith H. et al .
Cancer in universal and left-sided ulcerative colitis: Factors determining risk.
Gastroenterology.
1979;
77
290-294
- 27
Nugent F W, Haggitt R C, Gilpin P A.
Cancer surveillance in ulcerative colitis.
Gastroenterology.
1991;
100
1241-1248
- 28
Levin B.
Inflammatory bowel disease and colon cancer.
Cancer.
1992;
70
1313-1316
- 29
Pardi D S, Loftus E V, Kremers W K, Keach J, Lindor K D.
Ursodesoxycholic acid as a chemopreventive agent in patients with ulcerative colitis
and primary sclerosing cholangitis.
Gastroenterology.
2003;
124
889-893
- 30
Rubio C A, Befrits R.
Colorectal adenocarcinoma in Crohn's disease: A retrospective histologic study.
Dis Colon Rectum.
1997;
40
1072-1078
- 31
Friedman S, Rubin P H, Bodian C, Goldstein E, Harpaz N, Present D H.
Screening and Surveillance Colonoscopy in Chronic Crohn's Colitis.
Gastroenterology.
2001;
120
820-826
- 32
Greenstein A J, Sachar D B, Smith H, Janowitz H D, Aufses A H.
A comparison of cancer risk in Crohn's disease and ulcerative colitis.
Cancer.
1981;
48
2742-2745
- 33
Gyde S N, Prior P, Macartney J C, Thompson H, Waterhouse J A, Allan R N.
Malignancy in Crohn's disease.
Gut.
1980;
21
1024-1029
- 34
Choi P M, Zelig M P.
Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: Implications
for carcinogenesis and prevention.
Gut.
1994;
35
950-954
- 35
Gillen C D, Walmsley R S, Prior R, Andrews H A, Allan R N.
Ulcerative colitis and Crohn's disease: A comparison of the colorectal cancer risk
in extensive colitis.
Gut.
1994;
35
1590-1592
- 36
Itzkowitz S H, Greenwald B, Meltzer S J.
Colon carcinogenesis in inflammatory bowel disease.
Inflamm Bowel Dis.
1995;
1
142-146
- 37
Butt J H, Konishi F, Morson B C, Lennard-Jones J E, Ritchie J K.
Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis.
Dig Dis Sci.
1983;
28
18-26
- 38
Connell W R, Sheffield J P, Kamm M A, Ritchie J K, Hawley P R, Lennard-Jones J E.
Lower gastrointestinal malignancy in Crohn's disease.
Gut.
1994;
35
347-352
- 39
Hamilton S R.
Colorectal carcinoma in patients with Crohn's disease.
Gastroenterology.
1985;
89
398-407
- 40
Petras R E, Mir-Madjlessi S H, Farmer R G.
Crohn's disease and intestinalcarcinoma: A report of 11 cases with emphasis on associated
epithelial dysplasia.
Gastroenterology.
1987;
93
1307-1314
- 41
Fearon E R, Vogelstein B.
A genetic model for colorectal tumorigenesis.
Cell.
1990;
61
759-767
- 42
Vogelstein B, Fearon E R, Hamilton S R. et al .
Genetic alterations during colorectal-tumor development.
N Engl J Med.
1988;
319
525-535
- 43
Burmer G C, Levine D S, Kulander B G, Haggitt R C, Rubin C E, Rabinovitch P S.
c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma.
Gastroenterology.
1990;
99
416-420
- 44
Baker S J, Preisinger A C, Jessup J M. et al .
p53 gene mutations occur in combination with 17p allelic deletions as late events
in colorectal tumorigenesis.
Cancer Res.
1990;
50
7717-7722
- 45
Burmer G C, Rabinovitch P S, Haggitt R C. et al .
Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of
a p53 allele.
Gastroenterology.
1992;
103
1602-1610
- 46
Levin B.
Ulcerative colitis and colon cancer: biology and surveillance.
J Cell Biochem.
1992;
16 (Suppl)
47-50
- 47
Morson B C, Pang L SC.
Rectal biopsy as an aid to cancer control in ulcerative colitis.
Gut.
1967;
8
423-434
- 48
Melville D M, Jass J R, Morson B C.
Observer study of the grading of dysplasia in ulcerative colitis: comparison with
clinical outcome.
Hum Pathol.
1989;
20
1008-1014
- 49
Bernstein C N, Shanahan F, Weinstein W M.
Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?.
Lancet.
1994;
343
71-74
- 50
Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B.
Colonoscopic surveillance in long-standing total ulcerative colitis: A 15-year follow-up
study.
Gastroenterology.
1990;
99
1021-1031
- 51
Fresko D, Lazarus S S, Dotan J, Reingold M.
Early presentation of carcinoma of the small bowel in Crohn's disease (‘Crohn's carcinoma’).
Case reports and review of the literature.
Gastroenterology.
1982;
82
783-789
- 52
Korelitz B L, Lauwers G Y, Sommers S C.
Rectal mucosal dysplasia in Crohn's disease.
Gut.
1990;
31
1382-1386
- 53
Warren R, Barwick K W.
Crohn's colitis with adenocarcinoma and dysplasia. Report of a case and review of
100 small and large bowel resections for Crohn's disease to detect incidence of dysplasia.
Am J Surg Pathol.
1983;
7
151-159
- 54
Albert M B, Nochomovitz L E.
Dysplasia and cancer surveillance in inflammatory bowel disease.
Gastroenterol Clin North Am.
1989;
18
8397
- 55
Axon A T.
Cancer surveillance in ulcerative colitis: A time for reappraisal.
Gut.
1995;
36
801
- 56
Brostrom O, Lofberg R, Ost A, Reichar H.
Cancer surveillance of patients with long-standing ulcerative colitis: A clinical,
endoscopic, and histological study.
Gut.
1986;
27
1408-1413
- 57
Manning A P, Bulgim O R, Dixon M F, Axon A T.
Screening by colonoscopy for colonic epithelial dysplasia in inflammatory bowel disease.
Gut.
1987;
28
1489-1494
- 58
Ransohoff D F, Riddell R H, Levin B.
Ulcerative colitis and colonic cancer: Problems in assessing the diagnostic usefulness
of mucosal dysplasia.
Dis Colon Rectum.
1985;
28
383-388
- 59
Taylor B A, Pemberton J H, Carpenter H A. et al .
Dysplasia in chronic ulcerative colitis: Implications for colonoscopic surveillance.
Dis Colon Rectum.
1992;
35
950-956
- 60
Melville D M, Jass J R, Shepherd N A. et al .
Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes
in chronic ulcerative colitis. Observer variation and correlations.
Gastroenterology.
1988;
95
668-675
- 61
Dixon M F, Brown L J, Gilmour H M. et al .
Observer variation in the assessment of dysplasia in ulcerative colitis.
Histopathology.
1988;
13
385-387
- 62
Gorfine S R, Bauer J J, Harris M T, Kreel I.
Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?.
Dis Colon Rectum.
2000;
43
1575-1581
- 63
Blackstone M O, Riddell R H, Rogers B H, Levin B.
Dysplasia associated lesion or mass (DALM) detected by colonoscopy in long-standing
ulcerative colitis: An indication for colectomy.
Gastroenterology.
1981;
80
366-374
- 64
Schneider A, Stolte M.
Clinical and pathomorphological findings in patients with colorectal carcinoma complicating
ulcerative colitis.
Z Gastroenterol.
1993;
31
192-197
- 65
Konishi F, Wakasa H, Kino I.
Histological classification of the neoplastic changes arising in ulcerative colitis:
a new proposal in Japan.
J Gastroenterol.
1985;
30 (Suppl 8)
20-24
- 66
Tytgat G N, Dhir V, Gopinath N.
Dysplasien in flacher Mukosa. Endoscopic appearance of dysplasia and cancer in inflammatory
bowel disease.
Eur J Cancer.
1995;
31
1174-1177
- 67
Suzuki K, Muto T, Shinozaki M, Yokoyama T, Matsuda K, Masaki T.
Differential diagnosis of dysplasia-associated lesion or mass and coincidental adenoma
in ulcerative colitis.
Dis Colon Rectum.
1998;
41
322-327
- 68
Odze R D.
Adenomas and adenoma-like DALMS in chronic ulcerative colitis: A clinical, pathological
and molecular review.
Am J Gastroenterol.
1999;
94
1746-1750
- 69
Engelsgjerd M, Farraye F A, Odze R D.
Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic
ulcerative colitis.
Gastroenterology.
1999;
117
1288-1294
- 70
Rubin P H, Friedman S, Harpaz N. et al .
Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic
resection of dysplastic polyps.
Gastroenterology.
1999;
117
1295-1230
- 71
Odze R D, Brown C A, Hartmann C J, Noffsinger A E, Fogt F.
Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are
similar to non-colitic sporadic adenomas.
Am J Surg Pathol.
2000;
24
1209-1216
- 72
Torres C, Antonioli D, Odze R D.
Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic,
and follow-up study of 89 polyps from 59 patients.
Am J Surg Pathol.
1998;
22
275-284
- 73
Morin P J, Sparks A B, Korinek V. et al .
Activation of B-catenin-TcF signaling in colon cancer by mutations in B-catenin or
APC.
Science.
1997;
275
1787-1790
- 74
Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis B.
Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli
(APC) tumor-suppressor protein.
Proc Natl Acad Sci USA.
1995;
92
3046-3050
- 75
Rubin C E, Haggitt R C, Burmer G C, Brentnall T A, Stevens A C, Levine D S, Dean P J,
Kimmey M, Perera D R, Rabinovitch P S.
DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative
colitis.
Gastroenterology.
1992;
103
1611-1620
- 76
Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A,
Talbot I, Forbes A.
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Gastroenterology.
2004;
126
451-459
- 77
Woolrich A J, Da Silva B I, Korelitz B.
Surveillance in the routine management of ulcerative colitis: the predictive value
of low-grade dysplasia.
Gastroenterology.
1992;
103
431-438
- 78
Taylor B A, Pemberton J H, Carpenter H A.
Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance.
Dis Colon Rectum.
1992;
35
950-956
- 79
Allen D C, Hamilton P W, Watt P C, Biggart J D.
Morphometrical analysis in ulcerative colitis with dysplasia and carcinoma.
Histopathology.
1987;
11
913-923
- 80
Allen D C, Hamilton P W, Watt P C, Biggart J D.
Architectural morphometry in ulcerative colitis with dysplasia.
Histopathology.
1988;
12
611-621
- 81
Lennard-Jones J E, Morson B C, Ritchie J K. et al .
Cancer in colitis: Assessment of the individual risk by clinical and histological
criteria.
Gastroenterology.
1977;
73
1280-1287
- 82
Rozen P, Baratz M, Fefer F, Gilat T.
Low incidence of significant dysplasia in a successful endoscopic surveillance program
of patients with ulcerative colitis.
Gastroenterology.
1995;
108
1361-1370
- 83
Choi P M, Nugent F W, Schoetz D J, Silverman M L, Haggitt R C.
Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.
Gastroenterology.
1993;
105
418-424
- 84
Provenzale D, Wong J B, Onken J E, Lipscomb J.
Performing a cost-effectiveness analysis: Surveillance of patients with ulcerative
colitis.
Am J Gastroenterol.
1998;
93
872-880
- 85
Vemulapalli R, Lance P.
Cancer surveillance in ulcerative colitis: More of the same or progress?.
Gastroenterology.
1994;
107
1196-1199
- 86
Ullman T A, Loftus E V, Kakar S, Burgart L J, Sandborn W J, Tremaine W J.
The fate of low grade dysplasia in ulcerative colitis.
Am J Gastroenterol.
2002;
97
922-927
- 87
Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson P G, Ekbom A.
Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis?
A population based case control study.
Gut.
1998;
42
711-714
- 88
Lashner B A, Kane S V, Hanauer S B.
Colon cancer surveillance in chronic ulcerative colitis: Historical cohort study.
Am J Gastroenterol.
1990;
85
1083-1087
- 89
Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B.
DNA aneuploidy in ulcerative colitis: Reproducibility, topographic distribution, and
relation to dysplasia.
Gastroenterology.
1992;
102
1149-1154
- 90
Itzkowitz S H, Young E, Dubois D. et al .
Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: A retrospective
case-control study.
Gastroenterology.
1996;
110
694-704
- 91
Greenwald B D, Harpaz N, Yin J. et al .
Loss of heterozygosity affecting the p53, Rh, and mcc/apc tumor suppressor gene loci
in dysplastic and cancerous ulcerative colitis.
Cancer Res.
1992;
52
741-745
- 92
Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait.
Carcinoma and DNA aneuploidy in Crohn's colitis: A histological and flow cytometric
study.
Gut.
1991;
32
900-904
- 93
Tung B, Emond M J, Haggitt R C. et al .
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients
with ulcerative colitis and primary sclerosing cholangitis.
Ann Intern Med.
2001;
134
89-95
- 94
Kiesslich R, Fritsch J, Holtmann M. et al .
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia
and colon cancer in ulcerative colitis.
Gastroenterology.
2003;
124
880-888
- 95
Hontecillas R, Wannemeulher M J, Zimmerman D R. et al .
Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic
acid.
J Nutr.
2002;
132
2019-2027
- 96
Lashner B A.
Red blood cell folate is associated with the development of dysplasia and cancer in
ulcerative colitis.
J Cancer Res Clin Oncol.
1993;
119
549-554
- 97
Lashner B A, Heidenreich P A, Su G L, Kane S V, Hanauer S B.
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic
ulcerative colitis. A case-control study.
Gastroenterology.
1989;
97
255-259
- 98
Lashner B A, Provencher K S, Seidner D L, Knesebeck A, Brzezinski A.
The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative
colitis.
Gastroenterology.
1997;
112
29-32
- 99
Courtney E DJ, Melville D M, Leicester R J.
Review article: chemoprevention of colorectal cancer.
Aliment Pharmacol Ther.
2004;
19
1-24
- 100
Ryan B M, Russel M G, Langholz E, Stockbrugger R W.
Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
Am J Gastroenterol.
2003;
98
1682-1687
- 101
Eaden J.
Review article: The data supporting sa role for aminosalycylates in the prevention
of colorectal cancer in patients.
Aliment Pharmacol Ther.
2003;
18 (Suppl 2)
15-21
- 102
Eaden J A, Mayberry J F.
Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients
with inflammatory bowel disease.
Gut.
2002;
51 (Suppl 5)
10
- 103
Hanauer S B, Meyers S.
Practice guidelines. Management of Crohn's disease in adults.
Am J Gastroenterol.
1997;
92
559-566
Prof. Dr. med. Christoph Pohl
Medizinische Klinik · St. Elisabeth Krankenhaus Köln
Phone: 02 21-46 77-11 01
Fax: 02 21-46 77-11 08
Email: christoph.pohl@elisabeth-krankenhaus-koeln.de
Prof. Dr. Med. Wolfgang Kruis
Innere Abteilung · Evang. Krankenhaus Köln Kalk
Buchforststr. 2
51103 Köln
Phone: 02 21-82 89-52 89
Fax: 02 21-82 89-52 91